Dev4all partners with Pharmaseed to advance preclinical drug development

Dev4All, a cutting-edge R&D booster powered by 4P-Pharma, has announced a groundbreaking commercial partnership with Pharmaseed, a leading Contract Research Organisation (CRO) with over two decades of expertise in preclinical drug development. The strategic collaboration aims to revolutionise preclinical research by offering integrated, end-to-end solutions tailored to the needs of global biotech and pharmaceutical innovators.

This partnership seeks to address critical challenges in drug development, leveraging Dev4All’s innovative R&D capabilities and Pharmaseed’s comprehensive expertise. By combining their strengths, the two organisations promise to deliver comprehensive preclinical services, accelerate research timelines, and improve the global competitiveness of clients navigating the complexities of today’s R&D landscape.

Driving preclinical innovation through collaboration

Dev4All’s Executive Chair, Revital Rattenbach, shared that the collaboration signifies a major milestone in their pursuit of innovation. She described the partnership as a step forward in scaling capabilities to deliver customised, science-driven solutions while adhering to the highest standards of scientific rigour.

Pharmaseed’s Co-CEO, Shmuel Landau, highlighted the collaboration as an opportunity to integrate the company’s expertise with Dev4All’s advanced platform, expanding Pharmaseed’s reach in Europe. He emphasised their shared commitment to helping clients achieve clinical milestones faster through innovative preclinical strategies.

Delivering integrated preclinical services

The partnership aligns the strengths of two industry leaders to provide seamless preclinical solutions. Dev4All brings a decade of expertise in advancing drug candidates from Technology Readiness Level (TRL) 3 to 5, while Pharmaseed adds its reputation for delivering robust CRO services across diverse therapeutic areas. Together, the collaboration is poised to deliver tailored preclinical support and cutting-edge laboratory capabilities, offering clients a streamlined path to clinical trials.

Industry experts believe this partnership will have far-reaching implications for drug development, particularly for small and mid-sized pharmaceutical firms aiming to optimise R&D costs while accelerating timelines. The collaboration’s integrated approach to preclinical development is expected to attract companies seeking innovative solutions to navigate regulatory and market challenges.